Recent Progress in the Discovery of Allosteric Inhibitors of Kidney-Type Glutaminase.


Journal

Journal of medicinal chemistry
ISSN: 1520-4804
Titre abrégé: J Med Chem
Pays: United States
ID NLM: 9716531

Informations de publication

Date de publication:
10 01 2019
Historique:
pubmed: 4 7 2018
medline: 15 10 2019
entrez: 4 7 2018
Statut: ppublish

Résumé

Kidney-type glutaminase (GLS), the first enzyme in the glutaminolysis pathway, catalyzes the hydrolysis of glutamine to glutamate. GLS was found to be upregulated in many glutamine-dependent cancer cells. Therefore, selective inhibition of GLS has gained substantial interest as a therapeutic approach targeting cancer metabolism. Bis-2-[5-(phenylacetamido)-1,3,4-thiadiazol-2-yl]ethyl sulfide (BPTES), despite its poor physicochemical properties, has served as a key molecular template in subsequent efforts to identify more potent and drug-like allosteric GLS inhibitors. This review article provides an overview of the progress made to date in the development of GLS inhibitors and highlights the remarkable transformation of the unfavorable lead into "druglike" compounds guided by systematic SAR studies.

Identifiants

pubmed: 29969024
doi: 10.1021/acs.jmedchem.8b00327
pmc: PMC6335185
mid: NIHMS1003502
doi:

Substances chimiques

Enzyme Inhibitors 0
Sulfides 0
Thiadiazoles 0
bis-2-(5-phenylacetamido-1,2,4-thiadiazol-2-yl)ethyl sulfide 0
Glutaminase EC 3.5.1.2

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

46-59

Subventions

Organisme : NCI NIH HHS
ID : R01 CA193895
Pays : United States
Organisme : NINDS NIH HHS
ID : R21 NS074151
Pays : United States
Organisme : NIMH NIH HHS
ID : P30 MH075673
Pays : United States
Organisme : NIMH NIH HHS
ID : R25 MH080661
Pays : United States
Organisme : NCI NIH HHS
ID : F32 CA200278
Pays : United States

Références

Bioorg Med Chem. 2016 Apr 15;24(8):1819-39
pubmed: 26988803
Proc Natl Acad Sci U S A. 2016 Sep 6;113(36):E5328-36
pubmed: 27559084
Brain Behav Immun. 2017 Nov;66:135-145
pubmed: 28624534
J Biol Chem. 2017 Apr 14;292(15):6095-6107
pubmed: 28196863
Biochem J. 2007 Sep 15;406(3):407-14
pubmed: 17581113
ACS Med Chem Lett. 2016 Mar 13;7(5):520-4
pubmed: 27200176
J Med Chem. 2017 Jul 13;60(13):5599-5612
pubmed: 28609101
Proc Natl Acad Sci U S A. 2012 Jan 24;109(4):1092-7
pubmed: 22228304
Nature. 2013 Apr 4;496(7443):101-5
pubmed: 23535601
Cancer Res. 2010 Nov 15;70(22):8981-7
pubmed: 21045145
J Biol Chem. 2018 Mar 9;293(10):3535-3545
pubmed: 29317493
Drug Discov Today. 2014 Apr;19(4):450-7
pubmed: 24140288
Annu Rev Nutr. 1995;15:133-59
pubmed: 8527215
Cancer Cell. 2010 Sep 14;18(3):207-19
pubmed: 20832749
J Cell Biochem. 2014 Mar;115(3):498-509
pubmed: 24122876
Mol Cancer Ther. 2014 Apr;13(4):890-901
pubmed: 24523301
J Neuroimmune Pharmacol. 2013 Jun;8(3):594-607
pubmed: 23553365
Oncotarget. 2010 Dec;1(8):734-40
pubmed: 21234284
Mamm Genome. 2000 Dec;11(12):1107-10
pubmed: 11130979
Life Sci. 2008 May 23;82(21-22):1111-6
pubmed: 18452953
J Biol Chem. 1977 Mar 25;252(6):1927-31
pubmed: 845154
Cell Metab. 2012 Jan 4;15(1):110-21
pubmed: 22225880
Biochem J. 1981 Mar 1;193(3):709-16
pubmed: 7305957
Cell Metab. 2012 Feb 8;15(2):157-70
pubmed: 22326218
Physiol Genomics. 2002;9(3):157-66
pubmed: 12045296
Curr Mol Med. 2013 May;13(4):514-34
pubmed: 22934847
J Med Chem. 2012 Dec 13;55(23):10551-63
pubmed: 23151085
J Biol Chem. 1979 Apr 25;254(8):2835-8
pubmed: 429321
Mol Cancer Ther. 2012 Jun;11(6):1269-78
pubmed: 22496480
Future Med Chem. 2017 Jan;9(2):223-243
pubmed: 28111979
Future Med Chem. 2013 Sep;5(14):1685-700
pubmed: 24047273
Cancer Res. 2013 Jul 15;73(14):4190-5
pubmed: 23722553
Adv Neurobiol. 2016;13:1-7
pubmed: 27885624
Nat Rev Cancer. 2016 Oct;16(10):619-34
pubmed: 27492215
Biochemistry. 2011 Dec 20;50(50):10764-70
pubmed: 22049910
Cancer Biol Ther. 2012 Oct;13(12):1185-94
pubmed: 22892846
J Enzyme Inhib Med Chem. 2012 Dec;27(6):861-7
pubmed: 21999665
Physiol Rev. 1983 Apr;63(2):547-605
pubmed: 6132422
Bioorg Med Chem Lett. 2017 Mar 1;27(5):1243-1246
pubmed: 28174105
Nature. 2009 Apr 9;458(7239):762-5
pubmed: 19219026
Proc Natl Acad Sci U S A. 2012 May 15;109(20):7705-10
pubmed: 22538822
Oncotarget. 2016 Sep 6;7(36):57943-57954
pubmed: 27462863

Auteurs

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH